Barbara Broers
Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs
Fried R, Frei M, Schönbucher P, Kölliker C, Broers B, Isler M, Herold M, Schmid P, Oppliger R, Seidenberg A, Monnat M, Huber M. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion 2008; 78:123-30.
Jan 1, 2008Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs
Jan 1, 2008Digestion 2008; 78:123-30
Fried Ronald, Frei Markus, Schönbucher Peter, Kölliker Christoph, Broers Barbara, Isler Marc, Herold Markus, Schmid Patrick, Oppliger Robert, Seidenberg André, Monnat Martine, Huber Milo
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F, Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of hepatology 2005; 42:323-8.
Mar 1, 2005Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
Mar 1, 2005Journal of hepatology 2005; 42:323-8
Broers Barbara, Helbling Beat, François Anne, Schmid Patrick, Chuard Christian, Hadengue Antoine, Negro Francesco, Swiss Association for the Study of the Liver (SASL 18)